精準醫學時代下胰腺癌的診治_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 劉續寶 , 熊俊杰

四川大學華西醫院胰腺外科（成都 ?610041）;

Corresponding?author：

劉續寶, Email: xbliu@medmail.com.cn

Keywords：

DOI：

10.7507/1007-9424.201805098

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 劉續寶, 熊俊杰. 精準醫學時代下胰腺癌的診治. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(6): 641-644. doi: 10.7507/1007-9424.201805098 Copy

1.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018, 68(1): 7-30.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med, 2012, 366(6): 489-491.
4.	Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531(7592): 47-52.
5.	Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
6.	Zhang Y, Huang J, Chen M, et al. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology, 2012, 12(3): 227-233.
7.	Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology, 2011, 260(2): 446-453.
8.	Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging, 2011, 36(2): 179-184.
9.	Jha P, Bijan B, Melendres G, et al. Hybrid imaging for pancreatic malignancy: clinical applications, merits, limitations, and pitfalls. Clin Nucl Med, 2015, 40(3): 206-213.
10.	Kysucan J, Lovecek M, Klos D, et al. Benefit of PET/CT in the preoperative staging in pancreatic carcinomas. Rozhl Chir, 2010, 89(7): 433-440.
11.	Tatsumi M, Isohashi K, Onishi H, et al. ¹⁸F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int J Clin Oncol, 2011, 16(4): 408-415.
12.	Joo I, Lee JM, Lee DH, et al. Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology, 2017, 282(1): 149-159.
13.	Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with ¹⁸F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med, 2010, 51(5): 692-699.
14.	中華醫學會外科學分會胰腺外科學組. 胰腺癌診治指南(2014). 中華外科雜志, 2014, 52(12): 831-837.
15.	Richardson W, Stefanidis D, Mittal S, et al. SAGES guidelines for the use of laparoscopic ultrasound. Surg Endosc, 2010, 24(4): 745-756.
16.	Habr F, Akerman P. Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Front Biosci, 2000, 5: E30-E35.
17.	Yang R, Lu M, Qian X, et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J Cancer Res Clin Oncol, 2014, 140(12): 2077-2086.
18.	Gaujoux S, Allen PJ. Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy. World J Gastrointest Surg, 2010, 2(9): 283-290.
19.	Tran Cao HS, Kaushal S, Metildi CA, et al. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepatogastroenterology, 2012, 59(118): 1994-1999.
20.	王槐志. 可能切除胰腺癌的外科治療. 中華消化外科雜志, 2016, 15(6): 543-546.
21.	楊尹默. 可能切除的胰腺癌外科治療爭議與共識. 中國實用外科雜志, 2015, 35(1): 54-56.
22.	Laurence JM, Tran PD, Morarji K, et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg, 2011, 15(11): 2059-2069.
23.	White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am, 2004, 13(4): 675-684.
24.	Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol, 2017, 35(5): 515-522.
25.	Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phaseⅡtrial. Strahlenther Onkol, 2015, 191(1): 7-16.
26.	陳琦, 魏濤, 陳怡文, 等. 2017年美國臨床腫瘤學會年會胰腺癌研究進展解析. 中華消化外科雜志, 2017, 16(7): 684-688.
27.	Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol, 2013, 20(7): 2188-2196.
28.	Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008, 206(5): 833-846.
29.	Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
30.	Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2016, 34(21): 2541-2556.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018, 68(1): 7-30.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med, 2012, 366(6): 489-491.
4. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531(7592): 47-52.
5. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
6. Zhang Y, Huang J, Chen M, et al. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology, 2012, 12(3): 227-233.
7. Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology, 2011, 260(2): 446-453.
8. Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging, 2011, 36(2): 179-184.
9. Jha P, Bijan B, Melendres G, et al. Hybrid imaging for pancreatic malignancy: clinical applications, merits, limitations, and pitfalls. Clin Nucl Med, 2015, 40(3): 206-213.
10. Kysucan J, Lovecek M, Klos D, et al. Benefit of PET/CT in the preoperative staging in pancreatic carcinomas. Rozhl Chir, 2010, 89(7): 433-440.
11. Tatsumi M, Isohashi K, Onishi H, et al. ¹⁸F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int J Clin Oncol, 2011, 16(4): 408-415.
12. Joo I, Lee JM, Lee DH, et al. Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology, 2017, 282(1): 149-159.
13. Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with ¹⁸F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med, 2010, 51(5): 692-699.
14. 中華醫學會外科學分會胰腺外科學組. 胰腺癌診治指南(2014). 中華外科雜志, 2014, 52(12): 831-837.
15. Richardson W, Stefanidis D, Mittal S, et al. SAGES guidelines for the use of laparoscopic ultrasound. Surg Endosc, 2010, 24(4): 745-756.
16. Habr F, Akerman P. Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Front Biosci, 2000, 5: E30-E35.
17. Yang R, Lu M, Qian X, et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J Cancer Res Clin Oncol, 2014, 140(12): 2077-2086.
18. Gaujoux S, Allen PJ. Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy. World J Gastrointest Surg, 2010, 2(9): 283-290.
19. Tran Cao HS, Kaushal S, Metildi CA, et al. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepatogastroenterology, 2012, 59(118): 1994-1999.
20. 王槐志. 可能切除胰腺癌的外科治療. 中華消化外科雜志, 2016, 15(6): 543-546.
21. 楊尹默. 可能切除的胰腺癌外科治療爭議與共識. 中國實用外科雜志, 2015, 35(1): 54-56.
22. Laurence JM, Tran PD, Morarji K, et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg, 2011, 15(11): 2059-2069.
23. White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am, 2004, 13(4): 675-684.
24. Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol, 2017, 35(5): 515-522.
25. Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phaseⅡtrial. Strahlenther Onkol, 2015, 191(1): 7-16.
26. 陳琦, 魏濤, 陳怡文, 等. 2017年美國臨床腫瘤學會年會胰腺癌研究進展解析. 中華消化外科雜志, 2017, 16(7): 684-688.
27. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol, 2013, 20(7): 2188-2196.
28. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008, 206(5): 833-846.
29. Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
30. Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2016, 34(21): 2541-2556.

Previous Article
雙胎危重肺動脈瓣狹窄圍生期管理及新生兒期鑲嵌手術治療
Next Article
胰腺癌的新輔助治療

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

精準醫學時代下胰腺癌的診治

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content